Journal article
Evaluation of Interventions for Cognitive Symptoms in Long COVID
JAMA neurology, Vol.83(1), pp.49-59
01/01/2026
DOI: 10.1001/jamaneurol.2025.4415
PMID: 41212544
Abstract
This randomized clinical trial investigates if evidence-based rehabilitation strategies improve cognitive symptoms in persons with long COVID.
QuestionDo evidence-based rehabilitation strategies improve cognitive symptoms in persons with long COVID (ie, symptoms of fatigue, malaise, weakness, confusion that persist beyond 12 weeks after an initial COVID infection)?FindingsThis randomized clinical trial included 328 participants randomly assigned to 3 active interventions over 10 weeks at 22 clinical sites. None of the interventions demonstrated benefits on the modified Everyday Cognition Scale 2 in the intention-to-treat population by the end of the intervention period.MeaningThe trial failed to demonstrate differential benefits from online cognitive training, a structured cognitive rehabilitation program, or transcranial direct current stimulation in participants with cognitive long COVID.
ImportanceTreatment for cognitive dysfunction due to postacute sequelae of long COVID (ie, symptoms of fatigue, malaise, weakness, confusion that persist beyond 12 weeks after an initial COVID infection) remains a significant unmet need.ObjectiveTo test evidence-based rehabilitation strategies for improving cognitive symptoms in persons with long COVID.Design, Setting, and ParticipantsThis was a 5-arm, multicenter, randomized clinical trial of 3 remotely delivered interventions conducted between August 17, 2023, and June 10, 2024. The study took place at 22 trial sites and included the screening of individuals with cognitive long COVID.InterventionsParticipants were randomized to 1 of 5 arms: adaptive computerized cognitive training (BrainHQ [Posit Science]), cognitive-behavioral rehabilitation involving both group and individual counseling sessions (PASC-Cognitive Recovery [PASC-CoRE]) paired with BrainHQ, and transcranial direct current stimulation (tDCS) paired with BrainHQ. Two comparator arms were included as follows: unstructured computer puzzles and games (active comparator) and sham tDCS paired with BrainHQ. The interventions occurred 5 times per week over 10 weeks.Main Outcomes and MeasuresCognitive and behavioral in-person assessments were performed at baseline, midintervention, at the end of intervention, and 3 months after the end of the intervention. The primary outcome measure was the modified Everyday Cognition Scale 2 (ECog2) completed at the end of the intervention compared to the baseline visit based on participant self-report looking back over the prior 7 days.ResultsA total of 378 individuals were screened, from which there were 328 participants (median [IQR] age, 48.0 [37.0-58.0] years; 241 female [73.5%]; race: 15 Asian [4.6%], 47 Black [14.3%], and 235 White [71.6%]; ethnicity: 52 Hispanic [15.9%]). None of the 3 active interventions demonstrated benefits on the modified ECog2 in the intention-to-treat population by the end of the intervention period. The adjusted differences in mean change were 0.0 (95% CI, -0.2 to 0.2) for BrainHQ vs active comparator, 0.1 (95% CI, -0.1 to 0.3) for PASC-CoRE + BrainHQ vs active comparator, 0.0 (95% CI, -0.2 to 0.2) for tDCS-active + BrainHQ vs tDCS-sham + BrainHQ, and 0.1 (95% CI, -0.1 to 0.3) for PASC-CoRE + BrainHQ vs BrainHQ alone. Secondary participant-reported outcomes and neuropsychological tests showed no differential benefits for any treatment arm. All 5 arms demonstrated some improvements over time on the modified ECog2 and on secondary outcomes. There were no serious adverse events attributable to the interventions.Conclusions and RelevanceThis phase 2 randomized clinical trial failed to demonstrate differential benefits for online cognitive training, a structured cognitive rehabilitation program, and tDCS for cognitive long COVID.Trial RegistrationClinicalTrials.gov Identifier: NCT05965739.
Details
- Title: Subtitle
- Evaluation of Interventions for Cognitive Symptoms in Long COVID
- Creators
- David S. Knopman - Mayo ClinicDeborah Koltai - Duke UniversityDaniel Laskowitz - Duke UniversityJacqueline Becker - Icahn School of Medicine at Mount SinaiLeigh Charvet - New York UniversityJuan Wisnivesky - Icahn School of Medicine at Mount SinaiAlex Federman - Icahn School of Medicine at Mount SinaiAdam Silverstein - Duke UniversityYuliya Lokhnygina - Duke UniversityGiuseppina Pilloni - New York UniversityMichelle Haddad - Emory UniversityHenry Mahncke - Posit Science (United States)Tom Van Vleet - Posit Science (United States)Rong Huang - Duke UniversityWendy Cox - RECOVER Patient Caregiver Community Representat, Durham, NC USADiana Terry - RECOVER Patient Caregiver Community Representat, Durham, NC USAJeannie Karwowski - RECOVER Patient Caregiver Community Representat, Durham, NC USANetia McCray - RECOVER Patient Caregiver Community Representat, Durham, NC USAJenny J. Lin - Icahn School of Medicine at Mount SinaiGrace A. McComsey - Case Western Reserve UniversityUpinder Singh - University of IowaLinda N. Geng - Stanford UniversityHelen Y. Chu - University of WashingtonRebecca Reece - West Virginia UniversityJames Moy - Rush University Medical CenterZoe Arvanitakis - Rush University Medical CenterSairam Parthasarathy - University of ArizonaThomas F. Patterson - The University of Texas at San Antonio Health Science CenterAditi Gupta - University of Kansas Medical CenterLuis Ostrosky-Zeichner - The University of Texas Health Science Center at HoustonJeffrey Parsonnet - Dartmouth–Hitchcock Medical CenterElaine T. Kiriakopoulos - Dartmouth CollegeTamara G. Fong - Beth Israel Deaconess Medical CenterJanet Mullington - Harvard UniversitySarah Jolley - University of Colorado AnschutzNirav S. Shah - Endeavor HealthSarah Shizuko Morimoto - University of UtahJoyce K. Lee-Iannotti - Barrow Neurological InstituteWilliam D. S. Killgore - University of ArizonaBrigid Dwyer - Boston UniversityWilliam Stringer - University of California, Los AngelesCarmen Isache - University of FloridaJennifer A. Frontera - New York UniversityJerry A. Krishnan - University of Illinois ChicagoAshley O'steenMelissa James - Duke UniversityBarrie L. Harper - Duke UniversityKanecia O. Zimmerman - Duke UniversityRECOVER NEURO Clinical Trial Grp
- Resource Type
- Journal article
- Publication Details
- JAMA neurology, Vol.83(1), pp.49-59
- DOI
- 10.1001/jamaneurol.2025.4415
- PMID
- 41212544
- NLM abbreviation
- JAMA Neurol
- ISSN
- 2168-6149
- eISSN
- 2168-6157
- Publisher
- Amer Medical Assoc
- Number of pages
- 11
- Grant note
- National Institutes of Health; United States Department of Health & Human Services; National Institutes of Health (NIH) - USA
- Language
- English
- Date published
- 01/01/2026
- Academic Unit
- Internal Medicine
- Record Identifier
- 9985244549002771
Metrics
1 Record Views